Pekin Hardy Strauss Inc. Makes New Investment in Compass Pathways PLC Sponsored ADR $CMPS

Pekin Hardy Strauss Inc. bought a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 63,650 shares of the company’s stock, valued at approximately $792,000.

A number of other institutional investors have also recently made changes to their positions in CMPS. Ancora Advisors LLC bought a new position in shares of Compass Pathways during the 2nd quarter worth $43,000. EverSource Wealth Advisors LLC increased its holdings in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after acquiring an additional 1,920 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Compass Pathways in the 3rd quarter valued at about $85,000. Parallel Advisors LLC raised its stake in Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after acquiring an additional 7,183 shares during the period. Finally, North Star Investment Management Corp. raised its stake in Compass Pathways by 23.9% in the 3rd quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock valued at $116,000 after acquiring an additional 1,800 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Stock Performance

Shares of NASDAQ:CMPS traded up $0.80 during trading on Friday, hitting $8.61. 3,757,104 shares of the company were exchanged, compared to its average volume of 3,011,761. Compass Pathways PLC Sponsored ADR has a 52-week low of $4.88 and a 52-week high of $15.87. The stock has a 50 day moving average of $12.32 and a 200 day moving average of $10.41. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. The company has a market cap of $1.19 billion, a PE ratio of -2.47 and a beta of 2.43.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.08. As a group, equities research analysts predict that Compass Pathways PLC Sponsored ADR will post -0.83 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Morgan Stanley upped their price objective on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 target price on shares of Compass Pathways in a research note on Tuesday. B. Riley Financial lifted their target price on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a research report on Wednesday, September 9th. Finally, Wall Street Zen cut shares of Compass Pathways from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.14.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.